The results of using Pyrilutamide, a hair loss treatment available on the gray market, and other treatments such as Minoxidil, Finasteride and RU58841.
Pyrilutamide phase 3 results showed little to no significant hair regrowth, but may be sufficient for maintaining current hair density. The user is unsure due to lack of recent discussions on pyrilutamide.
The conversation discusses alternatives to RU58841 for hair loss treatment, with suggestions including topical spironolactone, peppermint and rosemary oils, and saw palmetto. The user also considers ordering RU58841 from China but finds it too expensive.
The conversation discusses treating male pattern baldness in a transgender woman using cyproterone acetate, finasteride, and biotin. The original poster shared their experience for others who might be in a similar situation.
RU58841 is discussed as a topical anti-androgen for hair loss, but its effectiveness and safety are not well-documented, leading to mixed opinions and experiences among users. Some combine it with finasteride, but concerns about side effects and lack of FDA approval limit its popularity.
Clascoterone and RU58841 are compared for effectiveness in treating hair loss. The discussion involves treatments like Minoxidil, finasteride, and RU58841.
The conversation discusses the storage and use of pyrilutamide for hair loss, where one user advises against keeping it in the freezer as it may crystallize the active compounds.
RU58841 is a strong non-steroidal antiandrogen for hair loss but may cause cardiovascular issues in some users. Alternatives like Pyrilutamide and Breezula are suggested due to better safety profiles and lower systemic risks.
A 32-year-old male experienced erectile dysfunction and decreased libido after using oral dutasteride and minoxidil for hair loss. He is considering switching to topical alternatives like Xyon dutasteride or RU58841 to reduce side effects.
A user shared their positive 3-month hair regrowth results using a 3-in-1 pill containing finasteride, minoxidil, and biotin, with no side effects. They also started microneedling, Nizoral, and caffeine shampoo to enhance growth.
The conversation discusses updates on hair loss treatments, specifically GT20029, PP405, and a rumored injectable peptide from UT. GT20029 is seen as a promising treatment expected within 5-7 years.
Tazarotene's potential to enhance Minoxidil conversion, similar to Tretinoin, is questioned. Users discuss the lack of information and seek further details.
Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.
Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.
The user is considering using RU58841 and pyrilutamide for hair loss, debating between powder and topical forms, and is currently using a combination of dutasteride, finasteride, minoxidil, tretinoin, and supplements. They report no significant side effects from finasteride and dutasteride, and are seeing some hair growth, but not on the scalp.
Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.
The conversation discusses using higher doses of minoxidil and finasteride, considering dutasteride, and exploring other treatments like RU58841 for hair preservation. The user reports no side effects after six months and is interested in advanced treatment combinations.
The conversation is about the lack of improvement in hair loss after using Pyrilutamide for 14 weeks, with the original poster unable to use Finasteride due to depression. Replies suggest that Pyrilutamide, like RU58841, may not work for everyone, and a more potent drug is being developed by Kintor.
The conversation is about using topical melatonin for hair loss and seeking advice on a safe mixing solution or pre-mixed product. Specific treatments mentioned are minoxidil, finasteride, and RU58841.
A 32-year-old male with diffuse thinning and seborrheic dermatitis has been using finasteride for 8 months without improvement. He is considering COQ10 + PQQ supplements for scalp inflammation and hair loss.
A user is seeking advice on a new topical hair loss treatment containing Minoxidil 3%, Finasteride 0.3%, Progesterone 1%, Hydrocortisone butyrate 0.1%, and Ketoconazole 0.5%. They are concerned about the systemic absorption of Finasteride and plan to do blood tests and a spermiogram before starting.
KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.
The conversation discusses sourcing Topilutamide (fluridil) as a treatment for hair loss, with users comparing it to RU58841 and finasteride. Users share their experiences with various treatments, including testosterone, DHT gel, and Proviron, while expressing difficulty in finding Topilutamide.
The conversation discusses skepticism over the results of Pyrilutamide for hair regrowth, suggesting that results from rigorous trials are more trustworthy. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation discusses the potential availability of a new hair loss treatment, GT20029, on the grey market, with users suggesting it could be within a year but advising against using grey market products due to safety concerns and complexity of the drug.
A user was prescribed betamethasone dipropionate spray for a receding hairline, which caused skin peeling and depigmentation. They stopped using it and are considering alternatives like BPC-157/TB-500 for healing.
The conversation is about purchasing KX-826 (Pyrilutamide) on Amazon, now called Koshine. A user mentioned their order is expected to arrive between August 22 and September 13.
The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.